- Home
- PVLA
as 05-09-2025 12:42pm EST
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
Upcoming Earnings Alert:
Get ready for potential market movements as Palvella Therapeutics Inc. Common Stock PVLA prepares to release earnings report on 15 May 2025.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WAYNE |
| Market Cap: | 280.4M | IPO Year: | N/A |
| Target Price: | $44.43 | AVG Volume (30 days): | 83.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.20 - $29.27 | Next Earning Date: | 05-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Palvella Therapeutics Inc. Common Stock News
PVLA Breaking Stock News: Dive into PVLA Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
GlobeNewswire
4 days ago
Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025
Insider Monkey
9 days ago
Why Palvella Therapeutics, Inc. (PVLA) is Surging in 2025
Simply Wall St.
13 days ago
One Palvella Therapeutics Insider Raised Their Stake In The Previous Year
GlobeNewswire
16 days ago
Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology
GlobeNewswire
17 days ago
Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
GlobeNewswire
a month ago
Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology
GlobeNewswire
a month ago
Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
Compare PVLA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PVLA Palvella Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.